Here we assessed characteristics of TIME in patients with or without KRAS mutation, to find out the underlying mechanisms especially that prevent KRAS-mutated CRC patients from benefiting from immunotherapy, and try to find the potential direction to transform these patients to be immunotherapy responders. The gene discussed is KRAS; the disease is colorectal carcinoma.